BrainStorm names ex-FDA official Peter Pitts executive chairman, Frenkel becomes senior adviser

• BrainStorm Cell Therapeutics named former FDA Associate Commissioner Peter J. Pitts executive chairman, adding the title of chief strategic regulatory and policy officer.
• Pitts takes day-to-day leadership of strategy, partnerships, investor engagement, clinical planning, with a mandate to run the upcoming NurOwn Phase 3b trial.
• Board Chairman Jacob Frenkel will step down into a senior adviser role as the company shifts into late-stage clinical execution.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brainstorm Cell Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-088728), on July 30, 2026, and is solely responsible for the information contained therein.